Secondary genomic alterations in non-Hodgkin’s lymphomas: tumor-specific profiles with impact on clinical behavior

Lymphoid neoplasms are associated with primary genetic alterations – mainly non-random reciprocal chromosomal translocations – and secondary alterations. In this perspective article, Drs. Bea and Campo discuss the importance of secondary chromosomal alterations in non-Hodgkin’s lymphomas. See related articles on pages 670, 680, and 688.

[1]  H. Müller-Hermelink,et al.  Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations , 2008, Haematologica.

[2]  R. Spang,et al.  Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma , 2008, Haematologica.

[3]  Juan F. García,et al.  Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia , 2008, Haematologica.

[4]  Jan Delabie,et al.  Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.

[5]  M. Kaminski,et al.  Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. , 2008, Cancer research.

[6]  L. Staudt,et al.  Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. , 2007, Blood.

[7]  Jan Delabie,et al.  Frequent occurrence of deletions in primary mediastinal B‐cell lymphoma , 2007, Genes, chromosomes & cancer.

[8]  R. Siebert,et al.  Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Mateo,et al.  MicroRNA losses in the frequently deleted region of 7q in SMZL , 2007, Leukemia.

[10]  H. Döhner,et al.  Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. , 2007, Best practice & research. Clinical haematology.

[11]  L. Staudt,et al.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Sonneveld,et al.  Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high‐dose chemotherapy in patients with multiple myeloma , 2007, British journal of haematology.

[13]  Liming Yang,et al.  A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.

[14]  Stefano Monti,et al.  Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma , 2006, The Journal of experimental medicine.

[15]  L. Staudt,et al.  Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. , 2005, Blood.

[16]  D. Pinkel,et al.  Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. , 2005, Blood.

[17]  D. Oscier,et al.  Splenic marginal zone lymphoma. , 2005, Blood reviews.

[18]  A. López-Guillermo,et al.  Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Ott,et al.  Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. , 2004, Blood.

[20]  H. Müller-Hermelink,et al.  VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. , 2003, Blood.

[21]  W. Chan,et al.  Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Siebert,et al.  Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Bosch,et al.  ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. , 2002, Blood.

[24]  A. López-Guillermo,et al.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. , 1999, Blood.